Home » Forskning på NET-kreft » MD, PhD Sven-Petter Haugvik talking about PNENs at CarciNor Annual Conference

MD, PhD Sven-Petter Haugvik talking about PNENs at CarciNor Annual Conference

MD, PhD Sven-Petter Haugvik gave a lecture at CarciNor Annual Conference in March, about pancreatic NET Cancer. Steve Jobs (1955-2011), co-founder of Apple Inc, was perhaps the most famous PNET patient. But most people think of his cancer as pancreatic and not pancreatic neuroendocrine cancer! Other “celebrities” has been more open about their diagnoses. Rock legend Wilko Johnson (also known from the TV-series Game of Thrones) was diagnosed in 2012. He talks about how surviving “terminal” cancer changed his life for the better. Dag Kittlaus, creator of speech recognition company Siri (which he sold to Apple in 2010), was also diagnosed with pancreatic neuroendocrine cancer in 2016.

Dr. Sven-Petter Haugvik

Dr. Sven-Petter Haugvik

Haugvik is a former research associate at Oslo University Hospital, and was awarded research funds from CarciNor’s Research Fund in 2011. He is currently working as a surgeon at Vestre Viken Hospital Trust.

The following text is an abstract of his doctoral thesis, Modern Surgical Treatment and Genomic Profiling of Pancreatic Neuroendocrine Neoplasms – from the Operating Theater to the Gene Lab (2016), dedicated to CarciNor!

Text and photo: Mari Sandvold, editor

Pancreatic neuroendocrine neoplasms (PNENs) comprise approximately five percent of neoplasms originating from the pancreas. Surgical resection is an important treatment option for PNENs because it alone offers the possibility of cure. To date, little academic study has been undertaken with regard to surgery for PNENs and therefore the scientific evidence underpinning operative decision-making in this area is limited.

One major aim of this thesis was to investigate clinical outcomes of modern surgical treatment for PNENs, including laparoscopic surgery, vascular reconstruction, and resection for high-grade neuroendocrine carcinoma. This was undertaken by a retrospective review of medical records at the largest tertiary care hospital in Norway which provides surgical treatment of PNENs and analysis of data from the Nordic neuroendocrine carcinoma registry. Laparoscopic surgery for PNEN cases was technically feasible in the majority of cases and with acceptable operative morbidity and good long-term prognosis. For patients with locally advanced PNENs, open pancreatic surgery with vascular reconstruction was feasible with acceptable surgical morbidity and short-term prognosis. In patients with high-grade pancreatic neuroendocrine carcinoma, combined surgical treatment and chemotherapy improved survival compared with chemotherapy alone.

At present, the clinical management of patients with PNEN is largely based on radiological staging and histopathological characteristics. However, the malignant potential of the individual tumor varies greatly and may not necessarily be predicted by histopathology. Thus, there is a need for better understanding of the geno-phenotypical relationship of these neoplasms.

A second major aim of this thesis was to identify genomic imbalance and genomic expression patterns that may be important for molecular differentiation of tumor aggressiveness in sporadic nonfunctioning PNENs. This was investigated by G-band karyotyping, high-resolution comparative genomic hybridization and RNA sequencing. In sporadic nonfunctioning PNENs, the number of genomic imbalances correlated with cell proliferation, tumor size and metastatic status. Loss of genomic material from chromosomal band 11p11 appeared to represent a primary pathogenetic event due to its high prevalence in small tumors with low cell proliferation activity. In sporadic nonfunctioning PNENs, higher cell proliferation activity and metastatic disease were associated with upregulation of genes involved in regulation of the cell cycle and cell division, such as those encoding Wnt signaling pathway proteins.

Overall, this thesis shows that selected cases of PNENs can be safely removed using modern surgical procedures. For the first time, and against prior assumptions, the data presented in this thesis supports the use of combined surgery and chemotherapy, as compared to chemotherapy alone, to improve overall survival of patients with high-grade pancreatic neuroendocrine carcinoma. Additionally, the thesis describes genomic imbalance and genomic expression patterns in sporadic nonfunctioning PNENs that could potentially contribute in prediction of the individual patient’s prognosis.

Text: MD, PhD Sven-Petter Haugvik

Modern Surgical Treatment and Genomic Profiling of Pancreatic Neuroendocrine Neoplasms – from the Operating Theater to the Gene Lab (2016)


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Follow on WordPress.com

Skriv din epostadresse for å følge denne bloggen og motta meldinger om nye artikler på epost.

Følg CarciNor på Twitter

Ronny Allan - Living with Neuroendocrine Cancer

Awareness of Neuroendocrine Cancer and associated issues. Supporting and helping NET Patients

Laurie Works

Intuitive Tarot Guidance

carcinor.wordpress.com/

CarciNor, for alle som er engasjert i NET-kreft

Kreftforeningens blogg

Sammen skaper vi håp

Beth's Adventures with Neuroendocrine Cancer

CarciNor, for alle som er engasjert i NET-kreft

The Daily Post

The Art and Craft of Blogging

The WordPress.com Blog

The latest news on WordPress.com and the WordPress community.

%d bloggers like this: